TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05812274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
Description: The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:~* ApricityCare™ Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.~* ApricityOncology™ Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.~* ApricityManage™ Dashboard - a dashboard intended for administrators, sponsors or funders to track program status.
Study: NCT06041789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Donepezil placebo tablet
Study: NCT06448806

Intervention type: OTHER
Group type: OTHER
Intervention: mobile health lifestyle intervention
Description: You will be asked to record all dietary and physical activity log for 12 months on an application. Mobile sms reminders will be sent to you on regular basis. At day 0, at 6th and 12 months you will be asked to provide 3 ml of blood for the methylation and advance glycation level testing and your weight and body fat percentage will be measured. During this period you will have to follow the lifestyle and diet chart provided to you by the researchers.
Study: NCT06259305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creation of a memory track combined with the baby's heartbeat
Description: This is as described above
Study: NCT06111261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: 200ml of 20% Human Serum Albumin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced crystalloid solution
Description: Balanced crystalloid solution
Study: NCT05908409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-121
Description: IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-121
Description: IDP-121 is a new chemical entity specifically designed to directly target cMyc protein that has demonstrated activity in multiple liquid and solid tumor cell lines and preclinical animal models
Study: NCT05281536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ppostural change from 45° to 10° in supine position
Description: The intervention will be a postural change from 45° to 10° in a semi-recumbent position of ARDS patients connected to mechanical ventilation.
Study: NCT05040841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S1/Text: Weekly check-in texts
Description: Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S1/Text: Weekly check-in texts
Description: Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S1/Text: Weekly check-in texts
Description: Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S1/Text: Weekly check-in texts
Description: Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent.
Study: NCT06508645

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP14012 injection
Description: 1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP14012 injection
Description: 1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP14012 injection
Description: 1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 injection
Description: 1. Part 1~   * Study drug: Daewoong Pharmaceutical Co., Ltd.; A mg, B mg, and C mg of DWP14012 inj. (40 mg/vial)~  * Control drug: Placebo (Normal saline)~2. Part 2 • Study drug: Daewoong Pharmaceutical Co., Ltd.; DWP14012 inj. (40 mg/vial)
Study: NCT05298995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CART01 (iC9-GD2-CAR T-cells)
Description: Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CART01 (iC9-GD2-CAR T-cells)
Description: Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CART01 (iC9-GD2-CAR T-cells)
Description: Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose
Study: NCT04829305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285
Description: SHR2285 is a selective inhibition of human FXIa small molecule compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285
Description: SHR2285 is a selective inhibition of human FXIa small molecule compound.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2285
Description: SHR2285 is a selective inhibition of human FXIa small molecule compound.
Study: NCT06301867

Intervention type: DIAGNOSTIC_TEST
Intervention: Plateau Pressure
Description: Plateau pressure will be measured on all patients in the participating intensive care units prior to extubation.
Study: NCT04813224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAUMA CENTERED EMDR-BASED TREATMENT and TRAUMA-FOCUSED CBT-BASED TREATMENT
Description: Psychological evidence-based intervention for the reduction of the impact of childhood sexual abuse.
Study: NCT05273216

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Duplex Sonography
Description: Immediately after mechanical thrombectomy, patients will be investigated with bedside neurosonography (including TCD) at the stroke unit or neurointensive care unit. Apart from routine assessment of brain-supplying vessels, experienced sonographers will especially focus on intracranial blood flow velocities and determine the MCA mean blood flow velocity index (recanalized divided by contralateral artery). To assess potential dynamic blood flow changes, these investigations will be repeated at 24-48 hours after thrombectomy and at day 7 when we expect a (more) stable stroke phase. During these neurosonographic assessments, other important and potentially influential (hemodynamic) parameters such as blood pressure, heart rate and use of vasoactive medications will be documented. Assessment of intracranial blood flow will be standardized to dedicated measuring points.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: The investigators will use magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) routinely performed on day 1 after thrombectomy to assess (1) the size and location of acute ischemic damage including (vasogenic) cerebral edema formation, (2) hemorrhagic transformation, (3) concomitant chronic ischemic and hemorrhagic brain changes, and (4) patency of intracranial vessels. Contrast-enhanced or arterial spin labeling perfusion MRI will be used to (5) measure cerebral perfusion status. Findings from perfusion MRI will be correlated with blood flow information from TCD. MRI including MRA and perfusion sequences will be interpreted centrally in Graz as successfully demonstrated in previous large multicenter stroke studies.
Study: NCT05040841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S1/Text: Weekly check-in texts
Description: Subject will receive weekly check-in texts in addition to the core adherence support component in the event they are identified as nonadherent and are linked with the Risk of Treatment Failure clinics. Subjects will be sent weekly simple but supportive text messages e.g. how are you? with the offer of a follow-up voice call for 16 consecutive weeks after being identified as nonadherent.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S2/Peer: Enhanced peer group support
Description: Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S2/Peer: Enhanced peer group support
Description: Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S2/Peer: Enhanced peer group support
Description: Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S2/Peer: Enhanced peer group support
Description: Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.
Study: NCT04813224

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRAUMA CENTERED EMDR-BASED TREATMENT and TRAUMA-FOCUSED CBT-BASED TREATMENT
Description: Psychological evidence-based intervention for the reduction of the impact of childhood sexual abuse.
Study: NCT05273216

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood biomarkers
Description: Apart from the assessment of outcome-relevant routine blood parameters of inflammation, coagulation, glucose metabolism, renal and liver function, the investigators will also investigate novel biomarkers of interest that could be indicative of endothelial damage / blood brain barrier disruption. Candidate markers for this purpose are interleukins (i.e., interleukin-6) and matrix metalloproteinases (i.e., MMP-9). Furthermore, the investigators will also measure neurofilament light chain protein as a marker for neuro-axonal damage that has been shown to indicate cerebral tissue destruction including vascular brain lesions with a very high sensitivity.~For analysis, peripheral blood will be taken by venipuncture on day one and at follow- up three months after MT. Serum will be immediately stored at -80°C according to international consensus guidelines. Markers will be centrally analyzed in the neurological laboratory of the Department of Neurology, Medical University of Graz.
Study: NCT05739695

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual bronchoscopy navigation
Description: It is planned to use VBN as the only navigation technique to compare it with rEBUS

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual bronchoscopy navigation
Description: It is planned to use VBN as the only navigation technique to compare it with rEBUS

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: radial EBUS
Description: It is planned to use rEBUS as the only navigation technique to compare it with VBN

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: radial EBUS
Description: It is planned to use rEBUS as the only navigation technique to compare it with VBN
Study: NCT06453369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Y shaped Tunnel with Connective tissue graft
Description: Sulcular incision followed by Micro-periosteal elevator will be used to elevate vertical full thickness tunnel starting coronally from the gingival sulcus and directed apically. CTG will be prepared and inserted into the coronal tunnel aperture using blunt instrument to facilitate intrusion of graft into tunnel. CTG insurted into the tunnel up to the apical level leaving a coronal part to completely cover the recession defect. Finally single interrupted suture will be used to secure the coronal exposed part of the CTG followed by sling suture fixation of the gingival flap with that of CTG. The donor CTG will be stabilized to the underlying connective tissue interproximally using 5.0 sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Y shaped Tunnel with Connective tissue graft
Description: Sulcular incision followed by Micro-periosteal elevator will be used to elevate vertical full thickness tunnel starting coronally from the gingival sulcus and directed apically. CTG will be prepared and inserted into the coronal tunnel aperture using blunt instrument to facilitate intrusion of graft into tunnel. CTG insurted into the tunnel up to the apical level leaving a coronal part to completely cover the recession defect. Finally single interrupted suture will be used to secure the coronal exposed part of the CTG followed by sling suture fixation of the gingival flap with that of CTG. The donor CTG will be stabilized to the underlying connective tissue interproximally using 5.0 sutures.
Study: NCT05313412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (comfilcon A lens)
Description: 6 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (comfilcon A lens)
Description: 6 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lehfilcon A lens)
Description: 6 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lehfilcon A lens)
Description: 6 hours
Study: NCT05094089

Intervention type: DEVICE
Intervention: Hernia repair with mesh
Description: Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery

Intervention type: DEVICE
Intervention: Hernia repair with mesh
Description: Hernia repair with GORE® SYNECOR Biomaterial; technical approach laparoscopic, robotic or open surgical / minimally invasive surgery
Study: NCT05190029

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Series of questions to parents of children in a virtual form.
Description: A questionnaire of 5 questions was provided in an online format addressed to the parents or legal representatives of each child. These questions were related to the child's own aspects (behavioral, psychomotor and cognitive parameters), as well as parameters oriented to the mother (pregnancy and childbirth).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention by teachers
Description: The school teachers examined neurobehavioral aspects of the students using the Battelle Developmental Inventory (BDI), which assesses five areas of development (personal/social, adaptive, motor, communicative and cognitive) between 2 and 8 years of age. The results are assigned in age-adjusted percentages, classified as: low (0-50%), normal (50-80%) and high (80-100%). Low and high values are considered impairments in one or more of the evaluated areas.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic evaluation
Description: A physiotherapeutic evaluation of the state of the RP and craniosacral system was performed according to the method of Andrzej Pilat and John E. Upledger.~The 14 primitive reflexes explored were: Moro reflex, cervical asymmetric, supine labyrinthine tonic, prone labyrinthine tonic, palmar grasp, plantar grasp, lateral trunk propulsion, parachute, Galant, search, cervical symmetric, Babinski, cochleo-palpebral and acoustic. These reflexes were considered as: inactive (0), or active (1).~In the evaluation of the craniosacral system, the following parameters were explored: dura mater sway, frontal bone, parietal bones, temporal bones, temporomandibular joint and sphenoid bone. These parameters were considered as: normal (0), or blockage (1).
Study: NCT05032716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exrcises
Description: the group (20 children) received traditional exercise program with instructions given to the children for 60 min aiming to improve posture control and balance. Tools of traditional physical therapy exercises were; special tools were used for traditional physical therapy exercises include vestibular board, rolls of different sizes, blocks and wedges of different heights

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exrcises and Treadmill training
Description: the group (20 children) received the same traditional physical therapy program as the same applied in group of balance exercises, in addition to treadmill training (30 min). The child walked on the treadmill (motorized treadmill, ENTRED, Enraf-Nonius) at 75% of over-ground speed and individually prescribed low-endurance walking at 0% incline for 20 min, three times a week for 8 successive weeks. The walking area of the treadmill is made from heavy steel with a minimum 8-inch thickness and is available with cushioning in case of accidental impacts. Before the walking session, each child underwent 5 min of active stretching exercises that include prolonged and progressive stretching of the hamstrings, quadriceps muscles, and Achilles tendon.
Study: NCT05017454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the optimized sodium valproate-loaded nanospanlastic dispersion
Description: participants will apply the optimized sodium valproate-loaded nanospanlastic dispersion twice daily, on the affected areas of the scalp for 3 months
Study: NCT05499793

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zingiber Officinale powder
Description: Ginger powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch powder
Study: NCT04562597

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose Response Curve Placebo
Description: 5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose Response Curve N-acetylcysteine 50 mg/kg
Description: 5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose Response Curve N-acetylcysteine 100 mg/kg
Description: 5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dose Response Curve N-acetylcysteine 150 mg/kg
Description: 5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
Study: NCT05017454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate lotion
Description: participants will apply marketed mometasone furoate lotion twice daily on the affected areas of the scalp for 3 months